İnterferon beta-1a kullanımına bağlı gelişen hepatotoksisite vakası

Öz

İnterferon β-1a, multipl skleroz tedavisinde yaygın olarak kullanılan immünomodülatör bir ilaçtır. Karaciğer fonksiyon bozukluğu bu ilacın yaygın bir yan etkisi olup genellikle interferon tedavisine başlandıktan sonraki ilk 6 ay içinde gelişir. Burada, interferon β-1a tedavisine sekonder hepatotoksisite gelişen vakamızı sunuyoruz.

Anahtar Kelimeler

• Multipl skleroz
• karaciğer fonksiyon bozukluğu
• interferon β

Hepatotoxicity case due to interferon beta-1a use

Öz

Interferon β-1a is an immunomodulatory drug widely used in the treatment of multiple sclerosis. Liver dysfunction is a common side effect of this drug and usually develops within the first 6 months of starting interferon therapy. Here, we present our case who developed hepatotoxicity secondary to interferon β-1a treatment.

Anahtar Kelimeler

• Multiple sclerosis
• liver dysfunction
• interferon β

Kaynakça

1. 1. Hauser SL, Bar-Or A, Comi G, et al; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221-34.
2. 2. No authors listed. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB multiple sclerosis study group. Neurology 1993;43:655-61.
3. 3. Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf 2003;26:815-27.
4. 4. M. Pulicken, A. Koteish, K. DeBusk, P.A. Calabresi. Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy. Neurology 2006;66:1954-5.
5. 5. Fontana RJ, Hayashi P, Bonkovsky HL, et al. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci 2013;58:1766-75.
6. 6. Andersen O, Elovaara I, Farkkila M, wt al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:706-10.
7. 7. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36.
8. 8. No authors listed. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504. Erratum in: Lancet 1999;353:678.

9. 9. Tremlett H, Seemuller S, Zhao Y, et al. Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients. Neurology 2006;67:1291-3.
10. 10. Chan S, Kingwell E, Oger J, Yoshida E, Tremlett H. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study. Mult Scler 2011;17:361-7.
11. 11. Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990;11:272-6.
12. 12. Björnsson E, Davíðsdóttir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2008;50:511-7.
13. 13. Itoh S, Marutani K, Matsuo S. Changes in ultrastructure of hepatocytes and liver test results before, during and after treatment with interferon-beta in patients with HBeAg positive chronic active hepatitis. Dig Dis Sci 1992;37:1260-7.
14. 14. Careli M, Porras MC, Rizzardini M, Cantoni L. Modulation of constitutive and inducible hepatic cytochrome P-450 by interferon beta in mice. J Hepatol 1996;24:230-7.
15. 15. Farnsworth A, Flaman A, Prasad SS, et al. Acetaminophen modulates the transcriptional response to recombinant interferon-beta. PLoS One 2010;5:11031.
16. 16. Olek MJ. Treatment of relapsing-remitting multiple sclerosis. http://www.uptodate.com/contents/search. Accessed 2 December 2012.